FIGURE 1.

Schematic illustration of SBI‐101‐01. A, Schematic of cell membrane interaction with blood flow. B, Extracorporeal circuit with integrated SBI‐101. The configuration enables in situ monitoring via extracapillary sampling. C, Study design. D, Sampling for exploratory endpoint analysis. AE, adverse event; AKI, acute kidney injury; AKI‐D, dialysis‐dependent acute kidney injury; CRRT, continuous renal replacement therapy; MSC, mesenchymal stem cell; MWCO, molecular weight cutoff; PD, pharmacodynamic; PK, pharmacokinetic; SAE, serious adverse event; T, time